Precision Proteomics: How to Enable Biomarker Identification in Health and Disease
About the webinar
Hear directly from Olink Proteomics® about precision protein analysis as a tool to improve health outcomes for patients with cancer, inflammatory, or age-related diseases. Learn how you can bring your protein biomarker discovery to the next level with Olink Proteomics Proximity Extension Assay (PEA) technology.
What you'll learn about
- Review of Olink's proteomics platform
- Use cases for actionable biomarker discovery
- Precision proteomics as a tool
- Specific ways to improve health outcomes for patients with cancer, inflammatory, or age-related diseases
About the Presenter
Michael Förster, Ph.D.
Scientific Director, Oncology and Rare Disease
Michael Förster joined Olink’s Scientific Affairs team as Director Oncology and Rare Disease. He completed his Ph.D. on autoimmune disease genetics at Karolinska Institute and moved to McGill University for a postdoc investigating the link between primary immunodeficiency, hematopoiesis, and the development of hematological malignancies.
He left academia for a stint at the Fraunhofer Society to manage projects in liquid biopsy-based cancer diagnostics and CAR-T cell therapy and more recently worked for Azenta Life Sciences as Scientific Liaison for biospecimen procurement and genomics services.